The Bcl10 gene, which encodes a protein with proapoptotic activity, recentl
y has been identified on chromosome 1p22. In this study, we analyzed somati
c mutations and deletions of the Bcl10 gene in a series of 439 tumor tissue
s from various histological origins that are known to have frequent loss of
heterozygosity at chromosome 1p22. According to the LOH study at intrageni
c polymorphic sites, deletion of Bcl10 in informative cases was detected in
50% of malignant mesotheliomas, 33% of gastric carcinomas, 23% of breast c
arcinomas, 20% of hepatocellular carcinomas, 17% of lymphomas, 15% of color
ectal carcinomas, 13% of laryngeal carcinomas, and 10% of male germ cell tu
mors (GCTs). In contrast, we detected Bcl10 mutations in 4 of 120 lymphomas
(3.3 %) and 2 of 78 GCTs (2.6%), respectively, but no mutation was found i
n the remaining solid tumors analyzed, Taken together, these data imply tha
t Bcl10 may occasionally be involved in the pathogenesis of lymphoma and GC
Ts, However, the absence or low frequency of the mutation suggests that eit
her Bcl10 is inactivated by other mechanisms or it is not the only target o
f chromosome 1p22 deletion in human tumors.